Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 68180-527 by Lupin Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Donepezil Hydrochloride - 3bfe818b 5567 4e5d 8204 1db3190c7169 01
Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - 3bfe818b 5567 4e5d 8204 1db3190c7169 02
Figure 2 - 3bfe818b 5567 4e5d 8204 1db3190c7169 03
This document seems to be a chart or graph displaying the cumulative percentage of patients in different treatment groups, with different dosages of Donepezil Hydrochloride and a placebo, and their corresponding change in ADAS-cog scores from baseline. The ADAS-cog is a metric used to measure cognitive function in patients with Alzheimer's disease. The chart appears to show that the group receiving the highest dose of donepezil (10 mg/day) experienced the smallest change in ADAS-cog scores from baseline, while the placebo group had the largest change in scores.*
Figure 3 - 3bfe818b 5567 4e5d 8204 1db3190c7169 04
This is a clinical trial report that compares the effectiveness of two different dosages of Donepezil Hydrochloride (10 mg/day vs. 5 mg/day) with a placebo in treating patients. The report indicates that the trial measures improvement in patients using the CIBIC-plus Rating scale, which evaluates for changes in cognitive abilities. However, the report does not provide any specifics on the results obtained from the trial.*
Figure 4 - 3bfe818b 5567 4e5d 8204 1db3190c7169 05
Figure 5 - 3bfe818b 5567 4e5d 8204 1db3190c7169 06
This appears to be a chart showing the cumulative percentage of patients based on their scores in a study, likely related to a treatment for Alzheimer's disease. The treatment options mentioned include a 10mg/day dose of Donepezil Hydrochloride, a 5mg/day dose of Donepezil Hydrochloride, and a placebo. There is also a column showing the change in ADAS-c09 scores with a percentage change of 74%, as well as some points indicating change from baseline. More specific information regarding the study and its findings cannot be determined from this text.*
Figure 6 - 3bfe818b 5567 4e5d 8204 1db3190c7169 07
This is a table showing the percentage of patients who have marked changes when administered with Donepezil Hydrochloride 10 mg/day or 5 mg/day, or a placebo, as measured by the CIBIC-plus Rating. The categories for change are "Markedly improved," "Moderately improved," "Minimally improved," "No change," "Minimally worse," "Moderately worse," and "Markedly worse."*
Figure 7 - 3bfe818b 5567 4e5d 8204 1db3190c7169 08
Figure 8 - 3bfe818b 5567 4e5d 8204 1db3190c7169 09
Figure 9 - 3bfe818b 5567 4e5d 8204 1db3190c7169 10
This is a description of a clinical trial in which the effects of Donepezil hydrochloride and a placebo on patients were evaluated. The text indicates that clinical improvement was observed in the group that received Donepezil hydrochloride, which increased over 3 months of drug treatment, while placebo led to a decline in clinical improvement. The description also indicates that a baseline was established at the start of the trial.*
Figure 10 - 3bfe818b 5567 4e5d 8204 1db3190c7169 11
Figure 11 - 3bfe818b 5567 4e5d 8204 1db3190c7169 12
This is a clinical study that involved treatment with Donepezil Hydrochloride at 23 mg/day and 10 mg/day dosages for an unspecified condition. The study lasted for weeks, and it showed notable improvements in clinical outcomes.*
Figure 12 - 3bfe818b 5567 4e5d 8204 1db3190c7169 13
Figure 13 - 3bfe818b 5567 4e5d 8204 1db3190c7169 14
This text appears to be a chart with medication dosage and a rating scale for patients taking Donepezil Hydrochloride. The chart details the percentage of patients whose condition improved or worsened, and the extent of the change from minimal to marked. The CIBIC-plus rating may be a method of assessing the effectiveness of the medication.*
DONEPEZIL HYDROCHLORIDE TABLETSRx Only23 mgNDC 68180-527-06 30 TABLETS - 3bfe818b 5567 4e5d 8204 1db3190c7169 15
This is a medicine label for Donepezil Hydrochloride tablets. It contains instructions for storage (protect from moisture) and dosage (30 tablets). The label also includes the name and strength of the medication, as well as the name and address of the manufacturer (Lupin). The prescription must be dispensed by a pharmacist and should be accompanied by a patient's prescription note.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.